Both the TRYPHAENA [10] as well as the KRISTINE [9] studies demonstrated the efficacy (pCR: 51.9% and 55.7%) and safety of the TCbHP regimen (six cycles) in the neoadjuvant treatment of HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.